The Journal of Clinical Investigation (Jul 2023)

Human endogenous retrovirus K contributes to a stem cell niche in glioblastoma

  • Ashish H. Shah,
  • Sarah R. Rivas,
  • Tara T. Doucet-O’Hare,
  • Vaidya Govindarajan,
  • Catherine DeMarino,
  • Tongguang Wang,
  • Leonel Ampie,
  • Yong Zhang,
  • Yeshavanth Kumar Banasavadi-Siddegowda,
  • Stuart Walbridge,
  • Dragan Maric,
  • Marta Garcia-Montojo,
  • Robert K. Suter,
  • Myoung-Hwa Lee,
  • Kareem A. Zaghloul,
  • Joseph Steiner,
  • Abdel G. Elkahloun,
  • Jay Chandar,
  • Deepa Seetharam,
  • Jelisah Desgraves,
  • Wenxue Li,
  • Kory Johnson,
  • Michael E. Ivan,
  • Ricardo J. Komotar,
  • Mark R. Gilbert,
  • John D. Heiss,
  • Avindra Nath

Journal volume & issue
Vol. 133, no. 13

Abstract

Read online

Human endogenous retroviruses (HERVs) are ancestral viral relics that constitute nearly 8% of the human genome. Although normally silenced, the most recently integrated provirus HERV-K (HML-2) can be reactivated in certain cancers. Here, we report pathological expression of HML-2 in malignant gliomas in both cerebrospinal fluid and tumor tissue that was associated with a cancer stem cell phenotype and poor outcomes. Using single-cell RNA-Seq, we identified glioblastoma cellular populations with elevated HML-2 transcripts in neural progenitor–like cells (NPC-like) that drive cellular plasticity. Using CRISPR interference, we demonstrate that HML-2 critically maintained glioblastoma stemness and tumorigenesis in both glioblastoma neurospheres and intracranial orthotopic murine models. Additionally, we demonstrate that HML-2 critically regulated embryonic stem cell programs in NPC-derived astroglia and altered their 3D cellular morphology by activating the nuclear transcription factor OCT4, which binds to an HML-2–specific long-terminal repeat (LTR5Hs). Moreover, we discovered that some glioblastoma cells formed immature retroviral virions, and inhibiting HML-2 expression with antiretroviral drugs reduced reverse transcriptase activity in the extracellular compartment, tumor viability, and pluripotency. Our results suggest that HML-2 fundamentally contributes to the glioblastoma stem cell niche. Because persistence of glioblastoma stem cells is considered responsible for treatment resistance and recurrence, HML-2 may serve as a unique therapeutic target.

Keywords